Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 6Breast 4Thoracic 3Gynecologic 3Genitourinary 3Gastrointestinal 2Head & Neck 1

Conditions

Urinary Bladder Neoplasms 9Prostatic Neoplasms 9Breast Neoplasms 8Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Urologic Neoplasms 4Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Urethral Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Gallbladder Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

Filgrastim 13Carboplatin 10Cyclophosphamide 9pembrolizumab 8Radiosurgery 8Ifosfamide 8Magnetic Resonance Spectroscopy 7Etoposide 7Biopsy 7Specimen Handling 6Doxorubicin 6X-Rays 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Paclitaxel 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cisplatin 5pazopanib 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Nivolumab 4Mesna 4Melphalan 4Docetaxel 4Busulfan 4Blood Specimen Collection 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma × Trastuzumab × Genitourinary × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Jonsson Comprehensive Cancer Center

Phase NA Completed
12 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡